Home > Inhibitors & Agonists > Tyrosine Kinase > Syk
Cat. No. Product name CAS No.
DC9632 BAY 61-3606 (dihydrochloride) Featured

BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

648903-57-5
DC10660 BAY 61-3606 free base Featured

BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

732983-37-8
DC7948 PRT-060318(PRT318) Featured

PRT-060318 is a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

1194961-19-7
DC1014 R406 free base Featured

R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.

841290-80-0
DC8733 R406 Featured

R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.

841290-81-1
DC9841 Fostamatinib(R788) Featured

R788 (Fostamatinib), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.

901119-35-5
DC1013 R788 disodium (Fostamatinib) Featured

R935788 (Fostamatinib disodium, R788) is a Syk inhibitor with IC50 of 41 nM.

1025687-58-4
DC9759 RO0921 Featured

RO0921 is a novel, potent SYK inhibitor.

1446790-62-0
DC10523 TAK-659 HCl Featured

TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.

1952251-28-3
DC28254 Lanraplenib monosuccinate

Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

1800046-97-2
DC28255 Lanraplenib succinate

Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

1800047-00-0
Page 1 / Total 1 FirstPrevNextLastGoto